James Paul Scopa has an estimated net worth of $159 Million. This is based on reported shares across multiple companies, which include Syndax Pharmaceuticals Inc, ARATANA THERAPEUTICS, INC., Cerecor Inc., MEMORY PHARMACEUTICALS CORP, Verastem, Inc., CHIASMA, INC, Radius Health, Inc., Epizyme, Inc., PEPLIN INC, TriVascular Technologies, Inc., DICE Therapeutics, Inc., Pacira Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., and Conatus Pharmaceuticals Inc.

2014 was James Paul Scopa's most active year for acquiring shares with 16 total transactions. James Paul Scopa's most active month to acquire stocks was the month of January. 2014 was James Paul Scopa's most active year for disposing of shares, totalling 12 transactions. James Paul Scopa's most active month to dispose stocks was the month of January. 2013 saw James Paul Scopa paying a total of $12,500,007.27 for 17,154,443 shares, this is the most they've acquired in one year. In 2013 James Paul Scopa cashed out on 14,314,805 shares for a total of $13,930,000.00, their largest year based on trade value.